medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2017, Number 03-04

Next >>

Medicina & Laboratorio 2017; 23 (03-04)

Resistance to inhibitors of the platelet receptor P2Y12: after aspirin, it was time to detect it and opt for a personalized management

Campuzano G

Language: Spanish
References: 32
Page: 109-112
PDF size: 261.95 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Srinath Reddy K, Katan MB. Diet, nutrition and the prevention of hypertension and cardiovascular diseases. Public Health Nutr 2004; 7: 167-186.

  2. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 3109-3116.

  3. Rigotti NA, Pasternak RC. Cigarette smoking and coronary heart disease: risks and management. Cardiol Clin 1996; 14: 51-68.

  4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.

  5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.

  6. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.

  7. World Health Organization. Global status report on noncommunicable diseases. Disponible en http://apps. who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1. Consultado febrero 2016 2014.

  8. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.

  9. Smith SC, Jr., Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001; 38: 1581-1583.

  10. AHA/ACC, National Heart L, Blood I, Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130-2139.

  11. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113: e409-449.

  12. King SB, 3rd, Smith SC, Jr., Hirshfeld JW, Jr., Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.

  13. Patrono C, Baigent C, Hirsh J, Roth G, American College of Chest P. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233S.

  14. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 670S-707S.

  15. Ackerman RH, Newman KL. Incomplete antiplatelet effect in patiens on aspirin compounds Ann Neurol 1990; 28: 224.

  16. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705-1709.

  17. Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002; 90: 893-895.

  18. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-238.

  19. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.

  20. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005; 115: 101-108.

  21. Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.

  22. Campuzano-Maya G. Resistencia a la aspirina: un problema letante de alto riesgo. . Medicina & Laboratorio 2016; 22: 411-448.

  23. Campuzano-Maya G. Inhibidores del receptor plaquetario P2Y12. Parte 2 de 2: etiología, diagnóstico y manejo de la resistencia. Medicina & Laboratorio 2017; 23: por definir.

  24. Hirsh J, Fuster V, Ansell J, Halperin JL, American Heart A, American College of Cardiology F. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-1711.

  25. Campuzano-Maya G. Resistencia a los inhibidores del receptor plaquetario P2Y12: después de la aspirina, llegó el momento de detectarla y de optar por un manejo personalizado. Medicina & Laboratorio 2017; 23: 113 -148.

  26. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231.

  27. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin «resistance» and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-198.

  28. Campuzano-Maya G. Inhibidores del receptor plaquetario P2Y12. Parte 1 de 2: escenario de acción, farmacología, aplicación clínica y limitaciones de su uso. 2017. Medicina & Laboratorio 2017; 23: 13-44.

  29. Eisenberg JM. The Agency for Healthcare Research and Quality: new challenges, new opportunities. Health services research 2000;35:xi-xvi.

  30. Plebani M, Lippi G. Improving diagnosis and reducing diagnostic errors: the next frontier of laboratory medicine. Clin Chem Lab Med 2016; 54: 1117-1118.

  31. Lippi G, Plebani M. Improving accuracy of diagnostic studies in a world with limited resources: a road ahead. Ann Transl Med 2016; 4: 43.

  32. Campuzano-Maya G. Editorial. Resistencia a la aspirina: llegó el momento de detectarla y de personalizar cada tratamiento. Medicina & Laboratorio 2016; 22: 9-12.




2020     |     www.medigraphic.com